Physician profile
Edison Rodrigues, SR.
NPI 1508864489
$1,304.24
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $74.41 · 2021: $432 · 2022: $268.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $384.69 | 2019-2022 | |
| Abbvie INC. | $262.53 | 2019-2021 | |
| Gilead Sciences, INC. | $231.08 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.19 | 2019-2022 | |
| Olympus America INC. | $97.05 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $84.59 | 2019-2021 | |
| Shionogi INC | $22.62 | 2019 | |
| Ambu INC. | $19.61 | 2021 | |
| Shire North American Group INC | $15.33 | 2019 | |
| Celgene Corporation | $14.84 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $10.71 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edison Rodrigues listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.